HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies

Molecular Diagnosis and Therapy

Volumn 17, Issue 2, 2013, Pages 85-99

  English, Diana P ^a   Roque, Dana M ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; APITOLISIB; BUPARLISIB; CANERTINIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; HER2 VACCINE; IDELALISIB; LAPATINIB; LEAD 212; LUMINESPIB; MARGETUXIMAB; NERATINIB; PACLITAXEL; PERTUZUMAB; PICTILISIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RETASPIMYCIN; TANESPIMYCIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHILL; COLLOID CARCINOMA; COLON CANCER; COLORECTAL CANCER; CYTOTOXICITY TEST; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EPISTAXIS; ERYTHEMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GYNECOLOGIC CANCER; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY CARCINOMA; METASTATIC MELANOMA; MYALGIA; OVARY CANCER; PAGET SKIN DISEASE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THROMBOCYTOPENIA; TUMOR BIOPSY; UPREGULATION; UTERINE CERVIX CANCER; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84877355892     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0024-9     Document Type: Review

References (129)

1. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol. 2001;28(5 Suppl 16):67-79. Epub 2001 Nov 14. (Pubitemid 33065112)
2. Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res. 2005;7(2):R256-66. Epub 2005 Mar 4.
3. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3(4):237-52. Epub 1999 Jul 1.
4. Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 2010;59(9):1295-312. Epub 2010 Jun 10.
5. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochimi Biophys Acta. 1994;1198(2-3):165-84. Epub 1994 Dec 30.
6. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene. 1995;159(1):19-27. Epub 1995 Jun 14.
7. Casalini P, Iorio MV, Galmozzi E, Menard S. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200(3):343-50. Epub 2004 Jul 16. (Pubitemid 39006925)
8. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996;15(2):254-64. Epub 1996 Jan 15. (Pubitemid 26029205)
9. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647-55. Epub 1997 Apr 1. (Pubitemid 27151960)
10. Busse D, Doughty RS, Arteaga CL. HER-2/neu (erbB-2) and the cell cycle. Semin Oncol. 2000;27(6 Suppl 11):3-8; discussion 92-100. Epub 2001 Mar 10. (Pubitemid 32172249)
11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12. Epub 1989 May 12. (Pubitemid 19147683)
12. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol. 2011;8(8):492-503. Epub 2011 Apr 7.
13. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev. 2006;32(3):180-90. Epub 2006 Feb 18.
14. Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Ruschoff J, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132(4):539-48. Epub 2009 Sep 19.
15. Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol. 2010;34(6):767-76. Epub 2010 Apr 28.
16. Dietel M, Ellis IO, Hofler H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch Int J Pathol. 2007;451(1):19-25. Epub 2007 Jun 15.
17. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5(3):199-207. Epub 2000 Nov 9.
18. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics. 2004;3(10):960-9. Epub 2004 Jul 9. (Pubitemid 40361231)
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. Epub 2007 Jan 1. (Pubitemid 46174133)
20. Ioannides CG, Ioannides MG, O'Brian CA. T-cell recognition of oncogene products: a new strategy for immunotherapy. Mol Carcinog. 1992;6(2):77-82. Epub 1992 Jan 1.
21. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, et al. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 1988;48(6):1517-20. Epub 1988 Mar 15. (Pubitemid 18091199)
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. Epub 1987 Jan 9. (Pubitemid 17231334)
23. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50(13):4087-91. Epub 1990 Jul 1. (Pubitemid 20225635)
24. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, et al. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer. 1994;73(1):148-53. Epub 1994 Jan 1. (Pubitemid 24012735)
25. Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON. 2012;17(2):277-83. Epub 2012 Jun 29.
26. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104(9):1372-6. Epub 2011 Apr 14.
27. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol. 2000;78(2):130-6. Epub 2000 Aug 6. (Pubitemid 30650342)
28. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004;23(3):200-5. Epub 2004 Jun 24. (Pubitemid 38857108)
29. Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008;21(9):1147-55. Epub 2008 Jun 24.
30. Sueblinvong T, Manchana T, Khemapech N, Triratanachat S, Termrungruanglert W, Tresukosol D. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer. Asian Pac J Cancer Prev. 2007;8(4):502-6. Epub 2008 Feb 12.
31. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, De Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441-53. Epub 2012 Feb 9.
32. Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T, Nonogaki H, et al. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows Arch A Pathol Anat Histopathol. 1992;421(5):393-400. Epub 1992 Jan 1.
33. Marinas MC, Mogos G, Ciurea R, Mogos DG. EGFR, HER2/neu and Ki67 immunoexpression in serous ovarian tumors. Rom J Morphol Embryol. 2012;53(3):563-7. Epub 2012 Sep 20.
34. Raspollini MR, Amunni G, Villanucci A, Castiglione F, Rossi Degl'Innocenti D, Baroni G, et al. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol. 2006;14(2):181-6. Epub 2006 Jun 21. (Pubitemid 43941182)
35. Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol. 2004;92(1):31-9. Epub 2004 Jan 31. (Pubitemid 38147368)
36. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004;95(3):570-5. Epub 2004 Dec 8. (Pubitemid 39592523)
37. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21(2):283-90. Epub 2003 Jan 15. (Pubitemid 46606157)
38. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol. 2004;15(1):104-12. Epub 2003 Dec 18. (Pubitemid 38145531)
39. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol. 2005;24(2):147-52. Epub 2005 Mar 23. (Pubitemid 40389539)
40. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433. Epub 2009 Dec 17.
41. Anglesio M, Kommoss S, Tolcher M, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 18% of carcinomas. J Pathol. 2012;229:111-20. Epub 2012 Aug 18.
42. Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol. 2011;64(12):1097-101. Epub 2011 Sep 8.
43. McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol. 2012;65(7):670-1; author reply 671-2. Epub 2012 Mar 14.
44. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PloS One. 2007;2(11):e1138. Epub 2007 Nov 8.
45. Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, et al. Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp. 2011;56:e3334. Epub 2011 Nov 9.
46. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res. 2011;17(6):1521-34. Epub 2011 Mar 18.
47. Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, et al. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res. 2002;93(11):1250-7. Epub 2002 Dec 4. (Pubitemid 36032989)
48. Uzan C, Darai E, Valent A, Graesslin O, Cortez A, Rouzier R, et al. Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch Int J Pathol. 2009;454(5):525-9. Epub 2009 Mar 19.
49. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer. 1995;75(8):2147-52. Epub 1995 Apr 15.
50. Peiro G, Mayr D, Hillemanns P, Lohrs U, Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Modern Pathol. 2004;17(3):227-87. Epub 2004 Jan 31.
51. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376-85. Epub 2006 May 20. (Pubitemid 46630670)
52. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15-20. Epub 2009 Oct 21.
53. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol. 1996;39(3):686-95. Epub 1996 Sep 1. (Pubitemid 26321381)
54. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol. 1994;54(3):264-8. Epub 1994 Sep 1. (Pubitemid 24301898)
55. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463-9. Epub 2003 Dec 17. (Pubitemid 38388137)
56. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93-108. Epub 1982 Mar 1. (Pubitemid 12108965)
57. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer. 2004;90(9):1814-24. Epub 2004 Jun 23. (Pubitemid 38725659)
58. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8(5):1271-9. Epub 2002 May 15. (Pubitemid 34517668)
59. Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18(2):138-43. Epub 1999 Apr 15. (Pubitemid 29153280)
60. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126-32. Epub 2004 Jul 31. (Pubitemid 41103726)
61. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813-8. Epub 2005 Mar 5. (Pubitemid 40311274)
62. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 2002;55(5):321-5. Epub 2002 May 3. (Pubitemid 34494168)
63. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57(23):5379-85. Epub 1997 Dec 11. (Pubitemid 27516377)
64. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006;100(3):561-4. Epub 2005 Nov 8. (Pubitemid 43246873)
65. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006;100(1):101-6. Epub 2005 Sep 15. (Pubitemid 41815057)
66. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;94(11):986-91. Epub 2003 Nov 13. (Pubitemid 37508982)
67. Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, et al. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol. 2012;31(3):211-21. Epub 2012 Apr 14.
68. Hale RJ, Buckley CH, Fox H, Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol. 1992;45(7):594-6. Epub 1992 Jul 1.
69. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, et al. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol. 2003;91(1):231-40. Epub 2003 Oct 8. (Pubitemid 37188617)
70. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990;76(3 Pt 1):381-7. Epub 1990 Sep 11. (Pubitemid 20264521)
71. Tebes S, Cardosi R, Hoffman M. Paget's disease of the vulva. Am J Obstet Gynecol. 2002;187(2):281-3; discussion 283-4. Epub 2002 Aug 24.
72. Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, et al. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol. 2010;63(6):544-7. Epub 2010 Apr 27.
73. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006;97(9):813-20. Epub 2006 Jun 30. (Pubitemid 44151259)
74. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, et al. Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PloS One. 2012;7(9):e45127. Epub 2012 Oct 3.
75. Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R, Cortes-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10(6):367-71. Epub 2008 Jun 19.
76. Miyamoto A, Akasaka K, Oikawa H, Akasaka T, Masuda T, Maesawa C. Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease. Am J Dermatopathol. 2010;32(6):578-85. Epub 2010 Jun 11.
77. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-6. Epub 2000 Mar 31. (Pubitemid 30208162)
78. Spiridon CI, Guinn S, Vitetta ES. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res. 2004;10(10):3542-51. Epub 2004 May 27. (Pubitemid 38685465)
79. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011;22(6):1302-7. Epub 2010 Nov 27.
80. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789-96. Epub 2008 Mar 19.
81. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650.x-5.x. Epub 2008 Mar 19.
82. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259-67. Epub 2006 Jan 13. (Pubitemid 43151545)
83. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72. Epub 2005 Oct 21. (Pubitemid 41464705)
84. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer. 2010;102(1):134-43. Epub 2009 Nov 19.
85. Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer. 2006;16(3):1370-3. Epub 2006 Jun 29. (Pubitemid 43886771)
86. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006;16(5):1897-902. Epub 2006 Oct 3. (Pubitemid 44470053)
87. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet. 2008;102(2):128-31. Epub 2008 Jun 17.
88. Alessandro S. Evaluation of carboplatin/paclitaxel with and without trastuzumab (Herceptin) in uterine serous cancer. http://www.clinicaltrials.gov/ ct2/show/NCT01367002?id=NCT01367002&rank=1. Accessed 2013 Mar 14.
89. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther. 2007;6(1):93-100. Epub 2007 Jan 24. (Pubitemid 46206671)
90. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer cell. 2002;2(2):127.x-37.x. Epub 2007 Jan 24.
91. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 2004;64(7):2601-9. Epub 2004 Apr 3. (Pubitemid 38523918)
92. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343-6. Epub 2004 Apr 3. (Pubitemid 38523885)
93. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005;104(12):2701-8. Epub 2005 Nov 3. (Pubitemid 41798280)
94. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91. Epub 2012 Oct 2.
95. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306(2):171.x-9.x. Epub 2012 Oct 2.
96. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010;3:7. Epub 2010 Feb 12.
97. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366.x-72.x. Epub 2010 Feb 12.
98. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-48. Epub 2004 Aug 17. (Pubitemid 39094044)
99. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23(6):488-96. Epub 2009 Jun 24.
100. Leslie M. Immunology. Regulatory T cells get their chance to shine. Science. 2011;332(6033):1020-1. Epub 2011 May 28.
101. Boyman O, Krieg C, Letourneau S, Webster K, Surh CD, Sprent J. Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Transpl Proc. 2012;44(4):1032-4. Epub 2012 May 9.
102. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122(3):1066-75. Epub 2012 Feb 14.
103. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1(2):118-29. Epub 2002 Mar 22. (Pubitemid 33741887)
104. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest. 2002;82(4):483-93. Epub 2002 Apr 16. (Pubitemid 34311120)
105. Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha, Fleuren GJ. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest. 1996;74(6):1039-49. Epub 1996 Jun 1. (Pubitemid 26182416)
106. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. 1996;149(1):129-42. Epub 1996 Jul 1. (Pubitemid 26230985)
107. Gelderman KA, Lam S, Gorter A. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert Opin Biol Ther. 2005;5(12):1593-601. Epub 2005 Dec 2. (Pubitemid 41771850)
108. Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer. 2012;106(9):1543-50. Epub 2012 Apr 26.
109. Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ, et al. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochimi Biophys Acta. 2010;1803(4):435-42. Epub 2010 Feb 2.
110. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29(23):3126-32. Epub 2011 Jul 7.
111. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010;28(34):5110-5. Epub 2010 Oct 27.
112. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008;272(2):296-306. Epub 2008 Sep 9.
113. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13(16):4909-19. Epub 2007 Aug 19. (Pubitemid 47294799)
114. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-38. Epub 2007 Apr 19. (Pubitemid 47073544)
115. Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, et al. EGFR/HER-targeted therapeutics in ovarian cancer. Futur Med Chem. 2012;4(4):447-69. Epub 2012 Mar 16.
116. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2(1):3-24. Epub 2002 Jan 5. (Pubitemid 34462457)
117. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32(3):517-30. Epub 2007 May 31. (Pubitemid 46708702)
118. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001;61(7):2945-52. Epub 2001 Apr 18. (Pubitemid 32691939)
119. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 2002;62(11):3132-7. Epub 2002 May 31. (Pubitemid 34602405)
120. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51(11):1780-7. Epub 2010 Nov 6.
121. Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2012. Epub 2012 Sep 18.
122. Behe M, Alt K, Deininger F, Buhler P, Wetterauer U, Weber WA, et al. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo. 2011;25(1):55-9. Epub 2011 Feb 2.
123. Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PloS One. 2012;7(8):e42345. Epub 2012 Aug 11.
124. Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pre-clinical assessment of Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease. Pharmaceuticals (Basel). 2011;5(1):1-15. Epub 2012 Jan 10.
125. 212Pb-TCMC-trastuzumab radio immunotherapy. http://www.clinicaltrials.gov/ct2/show/NCT01384253. Accessed 2013 Mar 14.
126. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother. 2012;61(5):629-41. Epub 2011 Oct 25.
127. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;155(4):1063-74. Epub 1982 Apr 1. (Pubitemid 12142723)
128. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-8. Epub 2006 Sep 9. (Pubitemid 46348738)
129. Baxevanis CN, Papamichail M, Perez SA. Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from phase/I and II clinical trials. Expert Rev Vaccines. 2012;11(6):637-40. Epub 2012 Aug 10.